Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA ® (pembrolizumab) Data
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma < /p > < p > Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new study findings investigating the use of KEYTRUDA < sup > ® < /sup >
(pembrolizumab), the company ’s anti-PD-1 therapy, across a range of
hematological cancers were presented at the 57 < sup > th < /sup > American
Society of Hematology (ASH) Annual Meeting. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items ...